Abstract
The authors describe a clinical observation of cardiotoxicity of anticancer targeted therapy in a young patient with HER2neu-positive breast cancer. The results of instrumental examinations demonstrating manifestations of cardiotoxicity are presented. The development of cardiovascular side effects against the background of anticancer treatment requires the appointment of cardioprotective therapy. Exogenous phosphocreatine (Neoton) can be considered as a cardioprotective agent, demonstrating efficacy in reversing cardiotoxicity induced by anti-HER2neu therapy.
Key words: cardiotoxicity, diagnostics, exogenous phosphocreatine, cardioprotection, treatment tactics.
Key words: cardiotoxicity, diagnostics, exogenous phosphocreatine, cardioprotection, treatment tactics.
For citation:Pylev A.L., Lisovoy V.A., Kozlova O.S. A clinical case of cardioprotective therapy with exogenous phosphocreatine during chemotherapy and anti HER2-neu therapy in a patient with breast cancer. Clinical review for general practice. 2023; 4 (12): 20–24 (In Russ.). DOI: 10.47407/kr2023.4.12.00325
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
